Scarica l'app Stockscreener
39.61
0.95%
-0.38
Dopo l'orario di chiusura:
39.11
-0.50
-1.26%
Collegium Pharmaceutical Inc Borsa (COLL) Ultime notizie
49,976 COLL shares flagged for sale (NASDAQ: COLL) - Stock Titan
Collegium, Paris Hilton announce ‘Embrace Your Sparkle’ campaign - TipRanks
Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community (2026-03-03) - Seeking Alpha
Collegium Pharmaceutical Faces Weak Start with 8.74% Gap Down Amid Market Concerns - Markets Mojo
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Momentum Shift: Does Collegium Pharmaceutical Inc offer margin of safety2025 Pullback Review & Weekly High Return Stock Forecasts - baoquankhu1.vn
Can Collegium Pharmaceutical Inc be the next market leaderMarket Growth Report & Reliable Price Breakout Signals - baoquankhu1.vn
Collegium to Participate in Upcoming Investor Conferences - The Manila Times
Collegium Pharmaceutical plans four Miami investor events in March - Stock Titan
Aug EndMonth: What are analysts price targets for Collegium Pharmaceutical IncShort Setup & Growth Oriented Trading Recommendations - baoquankhu1.vn
Collegium Pharmaceutical, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:COLL) 2026-03-01 - Seeking Alpha
A Look At Collegium Pharmaceutical (COLL) Valuation After Mixed Q4 2025 Results And Updated 2026 Guidance - simplywall.st
Collegium Pharmaceutical (NASDAQ:COLL) Lowered to Buy Rating by Wall Street Zen - MarketBeat
Why Collegium Pharmaceutical (COLL) Is Down 7.4% After Reaffirming 2026 Revenue Guidance Despite Earnings Miss - Yahoo Finance
Why Collegium Pharmaceutical (COLL) Stock Is Trading Lower Today - Finviz
Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA) - The Globe and Mail
Relative Strength Alert For Collegium Pharmaceutical - Nasdaq
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2025 Earnings Call Transcript - Insider Monkey
Collegium (COLL) Q4 2025 Earnings Call Transcript - AOL.com
Collegium Pharmaceutical (COLL) Margin Compression To 8.1% Tests Bullish Profitability Narrative - simplywall.st
Collegium Pharmaceutical Earnings Call: Jornay Leads Growth - TipRanks
Collegium Pharmaceutical reports Q4 adjusted EPS $2.04, consensus $2.14 - TipRanks
Collegium Pharmaceutical (NASDAQ:COLL) Announces Quarterly Earnings Results, Misses Expectations By $0.16 EPS - MarketBeat
Collegium Pharmaceutical: Q4 Earnings Snapshot - theheraldreview.com
Collegium Pharmaceutical, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Deep Dive Into Collegium Pharmaceutical Stock: Analyst Perspectives (5 Ratings) - Benzinga
Collegium Pharmaceutical (NASDAQ:COLL) Price Target Lowered to $54.00 at Needham & Company LLC - MarketBeat
Collegium Pharmaceutical (COLL) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates - Nasdaq
Earnings call transcript: Collegium Pharmaceutical Q4 2025 misses EPS forecast - Investing.com Nigeria
Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Down on Disappointing Earnings - MarketBeat
Collegium Pharmaceutical Q4 Adjusted Earnings, Net Product Revenue Rise - marketscreener.com
Collegium Pharmaceutical Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Collegium Pharmaceutical Q4 Earnings Call Highlights - Yahoo Finance
Collegium Pharmaceutical earnings missed by $0.10, revenue fell short of estimates - Investing.com UK
COLLEGIUM PHARMACEUTICAL ($COLL) Releases Q4 2025 Earnings - Quiver Quantitative
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for Full Year 2026 - marketscreener.com
Earnings Flash (COLL) Collegium Pharmaceutical, Inc. Posts Q4 Adjusted EPS $2.04 per Share, vs. FactSet Est of $2.14 - marketscreener.com
Collegium Pharmaceutical: Fourth Quarter Financial Overview - Bitget
Collegium Reports Record 2025 Results and Reaffirms Outlook - TipRanks
Collegium Pharmaceutical’s (NASDAQ:COLL) Q4 CY2025 Earnings Results: Revenue In Line With Expectations - Yahoo Finance
COLLEGIUM PHARMACEUTICAL, INC SEC 10-K Report - TradingView
Collegium (NASDAQ: COLL) outlines opioid, ADHD growth and rising generic threats - Stock Titan
Collegium (Nasdaq: COLL) posts record 2025 revenue and EBITDA - Stock Titan
Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results - GlobeNewswire
Collegium Pharmaceutical (COLL) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
Market Fear: Can Collegium Pharmaceutical Inc be the next market leader2025 Bull vs Bear & Long-Term Capital Growth Strategies - baoquankhu1.vn
Revenue Check: Is BULL stock a hidden gemQuarterly Earnings Summary & AI Driven Price Predictions - baoquankhu1.vn
Collegium Pharmaceutical earnings ahead: Jornay PM in focus - Investing.com South Africa
Collegium Pharmaceutical earnings ahead: Jornay PM in focus By Investing.com - Investing.com UK
Collegium Pharmaceutical (COLL) Q4 Earnings: What To Expect - Finviz
Is Collegium Pharmaceutical (COLL) Pricing Look Attractive After Strong Multi‑Year Share Gains? - simplywall.st
Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy? - Finviz
Price-Driven Insight from (COLL) for Rule-Based Strategy - Stock Traders Daily
Boston Legacy FC Announces Sensory Room Sponsorship with Collegium Pharmaceutical - Finviz
New sensory rooms aim to make Boston soccer games calmer - Stock Titan
Hillsdale Investment Management Inc. Acquires 25,100 Shares of Collegium Pharmaceutical, Inc. $COLL - MarketBeat
22,285 Shares in Collegium Pharmaceutical, Inc. $COLL Purchased by GSA Capital Partners LLP - MarketBeat
Can Collegium Pharmaceutical Inc. lead its sector in growthIPO Watch & Free Low Drawdown Momentum Trade Ideas - mfd.ru
Should I hold or sell Collegium Pharmaceutical Inc. nowRecession Risk & Precise Trade Entry Recommendations - mfd.ru
Collegium Pharmaceutical, Inc. (COLL) gains momentum on Jornay PM, Truist highlights robust pain portfolio - MSN
Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: 18.78% Potential Upside Beckons Investors - DirectorsTalk Interviews
Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards? - The Globe and Mail
MSN Money - MSN
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
0.21%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):